AR061362A1 - 4-oxo-tiazoles sustituidos como antagonistas del receptor cgrp, composicion farmaceutica que los comprende y el uso de los mismos en el tratamiento de enfermedades mediadas por el receptor cgrp. - Google Patents
4-oxo-tiazoles sustituidos como antagonistas del receptor cgrp, composicion farmaceutica que los comprende y el uso de los mismos en el tratamiento de enfermedades mediadas por el receptor cgrp.Info
- Publication number
- AR061362A1 AR061362A1 ARP070102587A ARP070102587A AR061362A1 AR 061362 A1 AR061362 A1 AR 061362A1 AR P070102587 A ARP070102587 A AR P070102587A AR P070102587 A ARP070102587 A AR P070102587A AR 061362 A1 AR061362 A1 AR 061362A1
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic
- ring
- optionally substituted
- heteroaryl
- independently selected
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 14
- 229910052760 oxygen Inorganic materials 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000002950 monocyclic group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 4
- 239000001301 oxygen Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 239000011593 sulfur Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 3
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 108091008648 NR7C Proteins 0.000 abstract 2
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 abstract 2
- -1 cycloaliphatic Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- GJGROPRLXDXIAN-UHFFFAOYSA-N 1,3-thiazol-4-one Chemical class O=C1CSC=N1 GJGROPRLXDXIAN-UHFFFAOYSA-N 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 235000019256 formaldehyde Nutrition 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000004793 spatially offset Raman spectroscopy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81317806P | 2006-06-13 | 2006-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061362A1 true AR061362A1 (es) | 2008-08-20 |
Family
ID=38832524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102587A AR061362A1 (es) | 2006-06-13 | 2007-06-13 | 4-oxo-tiazoles sustituidos como antagonistas del receptor cgrp, composicion farmaceutica que los comprende y el uso de los mismos en el tratamiento de enfermedades mediadas por el receptor cgrp. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2027106A2 (https=) |
| JP (1) | JP5382799B2 (https=) |
| CN (1) | CN101501009A (https=) |
| AR (1) | AR061362A1 (https=) |
| AU (1) | AU2007258294A1 (https=) |
| CA (1) | CA2655085A1 (https=) |
| IL (1) | IL195807A0 (https=) |
| MX (1) | MX2008015906A (https=) |
| NZ (1) | NZ574097A (https=) |
| TW (1) | TW200813019A (https=) |
| WO (1) | WO2007146349A2 (https=) |
| ZA (1) | ZA200810791B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834000B2 (en) * | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
| JP5451646B2 (ja) * | 2008-02-27 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤 |
| JP5923375B2 (ja) * | 2012-04-24 | 2016-05-24 | 花王株式会社 | Ｃｇｒｐ応答性促進剤 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| JO3669B1 (ar) * | 2015-01-06 | 2020-08-27 | Ferring Bv | بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين |
| WO2019112024A1 (ja) * | 2017-12-08 | 2019-06-13 | キッセイ薬品工業株式会社 | ピロリジン化合物 |
| EP3740477A1 (en) | 2018-01-19 | 2020-11-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| US20210121541A1 (en) * | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
| US20210130445A1 (en) * | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| EP4731613A1 (en) * | 2023-06-21 | 2026-04-29 | Valo Health, Inc. | Spirocyclic parp inhibitors and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52552B (sr) * | 2002-06-05 | 2013-04-30 | Bristol-Myers Squibb Company | Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom |
| TW200412948A (en) * | 2002-08-23 | 2004-08-01 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| EP1641423B1 (en) * | 2003-06-26 | 2010-03-17 | Merck Sharp & Dohme Corp. | Benzodiazepine cgrp receptor antagonists |
-
2007
- 2007-06-13 EP EP07796082A patent/EP2027106A2/en not_active Withdrawn
- 2007-06-13 MX MX2008015906A patent/MX2008015906A/es active IP Right Grant
- 2007-06-13 CA CA002655085A patent/CA2655085A1/en not_active Abandoned
- 2007-06-13 AR ARP070102587A patent/AR061362A1/es unknown
- 2007-06-13 JP JP2009515476A patent/JP5382799B2/ja not_active Expired - Fee Related
- 2007-06-13 AU AU2007258294A patent/AU2007258294A1/en not_active Abandoned
- 2007-06-13 ZA ZA200810791A patent/ZA200810791B/xx unknown
- 2007-06-13 CN CNA2007800297374A patent/CN101501009A/zh active Pending
- 2007-06-13 WO PCT/US2007/013896 patent/WO2007146349A2/en not_active Ceased
- 2007-06-13 NZ NZ574097A patent/NZ574097A/en not_active IP Right Cessation
- 2007-06-13 TW TW096121362A patent/TW200813019A/zh unknown
-
2008
- 2008-12-09 IL IL195807A patent/IL195807A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008015906A (es) | 2009-03-06 |
| NZ574097A (en) | 2012-01-12 |
| JP2009539997A (ja) | 2009-11-19 |
| ZA200810791B (en) | 2010-03-31 |
| AU2007258294A1 (en) | 2007-12-21 |
| WO2007146349A3 (en) | 2008-09-25 |
| CA2655085A1 (en) | 2007-12-21 |
| WO2007146349A2 (en) | 2007-12-21 |
| EP2027106A2 (en) | 2009-02-25 |
| CN101501009A (zh) | 2009-08-05 |
| TW200813019A (en) | 2008-03-16 |
| JP5382799B2 (ja) | 2014-01-08 |
| IL195807A0 (en) | 2009-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061362A1 (es) | 4-oxo-tiazoles sustituidos como antagonistas del receptor cgrp, composicion farmaceutica que los comprende y el uso de los mismos en el tratamiento de enfermedades mediadas por el receptor cgrp. | |
| AR068700A1 (es) | Antagonistas de receptores cgrp, composiciones farmaceuticas que los contienen, y usos de los mismos para el tratamiento de dolores, procesos inflamatorios y trastornos vasculares, y otras enfermedades | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
| AR065795A1 (es) | Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros. | |
| AR057034A1 (es) | Metodos para purificar tigeciclina | |
| AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
| AR066348A1 (es) | Inhibidores de las iap | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR078674A1 (es) | Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas | |
| AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
| AR041170A1 (es) | Derivados de bencimidazol, benzoxazol y benzotiazol | |
| AR059961A1 (es) | Compuesto derivado de fenil tetrahidro-indazol, composiciones farmaceuticas que lo comprenden, usos para preparar un medicamento para el tratamiento de una enfermedad mediada por una reduccion o desequilibrio en la funcion del receptor de glutamato y procesos para su preparacion | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| UY28692A1 (es) | Nuevos derivados de quinolina | |
| AR095340A1 (es) | Compuestos y sus usos para la modulación de hemoglobina | |
| HRP20170268T1 (hr) | Supstituirani benzodiazepeni kao modulatori receptora sličnih tollu | |
| AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| AR065891A1 (es) | Derivados de piridina y pirimidina como antagonistas del mglur2 | |
| AR068513A1 (es) | Moduladores tieno- y furo- pirimidina del receptor de histamina h4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |